Radiation-Induced Lung Injury Is Mitigated by Blockade of Gastrin-Releasing Peptide  by Zhou, Shutang et al.
The American Journal of Pathology, Vol. 182, No. 4, April 2013ajp.amjpathol.orgEPITHELIAL AND MESENCHYMAL CELL BIOLOGY
Radiation-Induced Lung Injury Is Mitigated by Blockade of
Gastrin-Releasing Peptide
Shutang Zhou,* Esther Nissao,* Isabel L. Jackson,y Wei Leong,* Lindsay Dancy,* Frank Cuttitta,z Zeljko Vujaskovic,y and
Mary E. Sunday*From the Departments of Pathology* and Radiation Oncology,y Duke University Medical Center, Durham, North Carolina; and the Radiation Oncology
Branch,z Angiogenesis Core Facility, National Cancer Institute, National Institutes of Health, Gaithersburg, MarylandAccepted for publicationC
P
hDecember 12, 2012.
Address correspondence to
Shutang Zhou, Ph.D., or Mary
E. Sunday, M.D., Ph.D., Duke
University Medical Center,
DUMC Box 3712, Durham,
NC 27710. E-mail: shutang.
zhou@duke.edu or mary.
sunday@duke.edu.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2012.12.024Gastrin-releasing peptide (GRP), secreted by pulmonary neuroendocrine cells, mediates oxidant-induced
lung injury in animal models. Considering that GRP blockade abrogates pulmonary inﬂammation and
ﬁbrosis in hyperoxic baboons, we hypothesized that ionizing radiation triggers GRP secretion, contrib-
uting to inﬂammatory and ﬁbrotic phases of radiation-induced lung injury (RiLI). Using C57BL/6 mouse
model of pulmonary ﬁbrosis developing20 weeks after high-dose thoracic radiation (15 Gy), we injected
small molecule 77427 i.p. approximately 1 hour after radiation then twice weekly for up to 20 weeks.
Sham controls were anesthetized and placed in the irradiator without radiation. Lung parafﬁn sections
were immunostained and quantitative image analyses performed. Mice exposed to radiation plus PBS had
increased interstitial CD68þ macrophages 4 weeks after radiation and pulmonary neuroendocrine cells
hyperplasia 6 weeks after radiation. Ten weeks later radiation plus PBS controls had signiﬁcantly increased
pSmad2/3þ nuclei/cm2. GRP blockade with 77427 treatment diminished CD68þ, GRPþ, and pSmad2/3þ
cells. Finally, interstitial ﬁbrosis was evident 20 weeks after radiation by immunostaining for a-smooth
muscle actin and collagen deposition. Treatment with 77427 abrogated interstitial a-smooth muscle actin
and collagen. Sham mice given 77427 did not differ signiﬁcantly from PBS controls. Our data are the ﬁrst
to show that GRP blockade decreases inﬂammatory and ﬁbrotic responses to radiation in mice. GRP
blockade is a novel radiation ﬁbrosis mitigating agent that could be clinically useful in humans exposed to
radiation therapeutically or unintentionally. (Am J Pathol 2013, 182: 1248e1254; http://dx.doi.org/
10.1016/j.ajpath.2012.12.024)Supported by a RadCCore Pilot grant AI-067798-02 (M.E.S.) (program
director: M. Dewhirst, Center for Medical Countermeasures Against
Radiation Injury, University of Pittsburgh, Pittsburgh, PA, and Duke
University, Durham, NC).
Disclosure: F.C. has a patent on 77427 as a treatment for cancer.
Current address of I.L.J. & Z.V., Department of Radiation Oncology,
University of Maryland, Baltimore, Maryland.Radiationﬁbrosis is a serious complication that affects normal
lung following unintentional exposure or due to therapeutic
ionizing radiation of thoracic tumors. Despite advances in
radiobiology, precisemechanisms bywhich radiation induces
lung injury remain controversial.1 Classically, radiation-
induced lung injury (RiLI) is characterized by a latent
period that can last for weeks to months after radiation
exposure, followed by 2 stages of overt lung injury that can
lead to life-threatening and debilitating pulmonary toxic
effects.2,3Acute inﬂammatory lung injury arises 1 to 6months
after radiation exposure,with diffuse alveolar damage, similar
to acute respiratory distress syndrome. Later, chronic inter-
stitial and intra-alveolar ﬁbrosis develops, predominantly in
irradiated segments, with myoﬁbroblast proliferation and
collagen deposition. It is unclear why only approximately
15% of radiation-exposed patients develop RiLI.1,4 Generalstigative Pathology.
.cytoprotective agents, such as a catalytic antioxidant metal-
loporphyrin (AEOL10113), can reduce the severity of RiLI
by decreasing free radical injury after radiation.5
Our novel paradigm links gastrin-releasing peptide (GRP)
to radiation lung injury. We hypothesized that GRP is a medi-
ator of RiLI: promoting both macrophage accumulation and
ﬁbrosis.We propose that ionizing radiation triggers pulmonary
neuroendocrine cell (PNEC) hyperplasia, leading to GRP
secretion, which then mediates chronic lung injury. GRP
GRP and Radiation Fibrosisreceptor (GRPR) gene expression is detected and functional in
pulmonary epithelial cells, ﬁbroblasts, endothelial cells, and
macrophages.6e10GRP is a proinﬂammatoryneuropeptide that
functions as an inﬂammatory cell activator, mitogen, and cell
differentiation factor.8,10,11 GRP is expressed at the highest
levels in PNEC in fetal lung,12 where it can promote lung
development.13 After birth, GRP production normally
decreases, but elevated levels are associated with many in-
ﬂammatory lung conditions, including chronic lung disease of
newborns (bronchopulmonary dysplasia).14e17 PNEC hyper-
plasia can be triggered by inﬂammation or exposure to oxygen
or ozone10,16,18 and can take weeks to reach peak levels.19
The present investigation tests the hypothesis that GRP
contributes to radiation-induced pulmonary ﬁbrosis in
C57BL/6 mice. One hour post exposure to thoracic radiation
(15 Gy), we treated mice i.p. with either PBS or GRP
blockade by using small molecule 77427. We have quan-
tiﬁed results of immunohistochemistry (IHC) by using
image analysis with ImageJ version 1.46e (NIH, Bethesda,
MD) to determine whether GRP contributes to radiation-
induced inﬂammatory responses and/or ﬁbrosis, speciﬁcally
including assessment of active transforming growth factor
(TGF)-b signaling.
Materials and Methods
Mice
C57BL/6mice at 8 weeks of age (Charles River Laboratories,
Morrisville, NC) were selected for these experiments because
they are susceptible to radiation ﬁbrosis.20e22 Females were
used because GRPR is X-linked and females have twice the
level of GRPR gene expression as males.23
Radiation and 77427 Treatment Regimen
Radiation dose and uniformity of distribution were deter-
mined before initiating the study as described.24 In brief, X-
ray dosimetry was performed using a calibrated ionization
chamber,25,26 with dose rate variation across the ﬁeld being
<6%. Validation and quality assurance of the set-up were
performed in mice, and the total accumulated dose differed
by 5% different from the calculated dose.
Before irradiation, mice were anesthetized with 100 mg/kg
of ketamine and 10 mg/kg of xylazine. Ten mice were
simultaneously irradiated in the prone position with 15 Gy of
320-kVp X-rays delivered to the thorax (Precision X-ray Inc.,Table 1 Antibodies used for IHC
Antibody Clone/catalog no. Source
GRP 2A11 (mouse) F. Cuttitta
PGP9.5 Z5116 (rabbit) Dako (Carpinte
CD68 MCA1957 (rat) AbD Serotec (R
pSmad2/3 sc-11769 (goat) Santa Cruz Bio
aeSMA Clone 1A4/A5691 (mouse) Sigma-Aldrich
The American Journal of Pathology - ajp.amjpathol.orgNorth Branford, CT; half value layer Z 1.00 mm Cu, dose
rateZ 69 cGy/min) via adjustable apertures with 8-mm lead
shielding of the head and abdomen. These dose rates produce
equivalent lung damage without radiation dose sparing.27
Sham-irradiated animals were treated similarly, except that
the radiation source was not turned on.
At approximately 1 hour after radiation, mice were
injected i.p. with 0.1 mL of either PBS or 77427 (10 nmol
per mouse Z 500 nmol/L ﬁnal). This dose was previously
determined to be optimal in suppressing inﬂammatory
responses in mouse lung.10 Mice were analyzed for all
markers at 2, 4, 6, 8, 10, and 20 weeks after radiation.
Antibodies and IHC
Antibodies were all available commercially from vendors as
listed in Table 1. Antibody dilutions and slide pretreatments
are also listed in Table 1. The avidin-biotin complex tech-
nique of IHC was used as detailed elsewhere.28 For most
antibodies, the peroxidase method was used with dia-
minobenzidine as substrate, except for a-smooth muscle
actin (SMA) staining, which used alkaline phosphatase-
conjugated anti-SMA with the Vector Red substrate
(Vector Laboratories, Burlingame, CA).
Computerized Quantitative Image Analysis
Slides from the four groups (eight mice per group at each time
point) of experimental mice (radiation versus sham, injected
with PBS or 77427 in PBS) were viewed by a board-certiﬁed
anatomical pathologist using bright ﬁeld microscopy at all
time points (weeks 2, 4, 6, 8, 10, and 20 after radiation). For
CD68-, pSmad2/3-, SMA-, and Trichrome-positive cells, 10
to 15 random photomicrographs of the alveoli were taken at
40 magniﬁcation within 1 mm of the pleural surface,
including 3 to 4 images per lobe for all three lobes of lung
that were parafﬁn embedded (left upper, left lower, and right
upper).
For CD68 and pSmad2/3 image analysis, numbers of posi-
tive cells were quantiﬁed by thresholding the images, binary
conversion, and counting the number of positive particles >2
and <20 mm by using ImageJ version 1.46e. The total area of
tissue per photomicrographwas determined by thresholding all
of the tissue, followed by binary conversion and measurement
of the tissue area.
For GRP and PGP9.5, all positive cells per slide were
counted manually because they most often occur in clustersDilution Reference
1:200 10
ria, CA) 1:200 25
aleigh, NC) 1:100 29
technology (Santa Cruz, CA) 1:100 30
(St. Louis, MO) 1:60 31
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Figure 1 GRP blockade with 77427 abrogates peak CD68þmacrophages in
mouse lungs at 4 weeks after radiation. A: Sham plus PBS group. CD68 im-
munostaining detects few alveolar and tissue macrophages in Sham controls
(arrows). B: Radiation plus PBS group. After radiation there was a signiﬁcant
increase in CD68þ cells (arrowheads) in the alveolar interstitium. C: Radiation
plus 77427 group. CD68þ cells diminished to baseline values in mice given
77427 twice a week after radiation. D: Image analysis. * P < 0.00001 for
radiation plus PBS versus either sham plus PBS, sham plus 77427, or radiation
plus 77427. Scale bars: 25 mm (AeC). V, blood vessel.
Figure 2 GRP blockade reduces peak numbers of PNECs at 6 weeks after
radiation. A: Sham plus PBS controls have rare GRPþ cells (black arrow) most
often at branch points in the airways (GRP immunostaining). B: Six weeks after
radiation, there are numerous GRPþ cells in distal bronchiolar epithelium
(many indicated by arrows). Most GRPþ cells are also PGP9.5þ (DeF),
consistent with a neuroendocrine phenotype (GRP immunostaining). Many of
these cells in irradiated mice given PBS are also CC10þ (unpublished data),
consistent with a multipotent epithelial phenotype emerging after radiation.
C: Mice exposed to radiation and then injected with 77427 twice a week have
fewer GRPþ cells in bronchiolar epithelium at 6 weeks (GRP immunostaining).
D: Sham plus PBS controls have rare PGP9.5þ cells (none in this ﬁeld) despite
strong positive control staining for PGP9.5 in nerve ﬁbers (white arrows in
right lower corner) (PGP9.5 immunostaining). E: Six weeks after radiation,
there are numerous PGP9.5þ cells in distal bronchiolar epithelium (arrows)
(PGP9.5 immunostaining). PGP9.5þ cells are also positive for GRP (AeC) and
CC10 (not shown), consistent with a multipotent epithelial phenotype after
radiation. F: Mice exposed to radiation then injected with 77427 twice a week
have fewer PGP9.5þ cells in bronchiolar epithelium at 6 weeks (PGP9.5 im-
munostaining). G: Quantitative image analysis shows a large increase in GRPþ
and PGP9.5þ cells in lungs of mice exposed 6 weeks earlier to radiation, which
is signiﬁcantly decreased by treatment with 77427. Compared with sham
controls, *P< 0.001 and zP< 0.01 for either #GRPþ foci per cm2 or #PGP9.5þ
cells/cm2 in radiation-treated lung tissue area. Compared with radiation-
treated mice; yP < 0.01 for either xP < 0.04 (PGP9.5) for mice exposed to
radiation, then further injected with 77427 twice a week. Scale bars: 25 mm
(AeF). L, airway lumen; V, blood vessel.
Zhou et althat are not recognized as separate cells by ImageJ. This was
achieved by counting numbers of nuclei present in cells with
immunopositive cytoplasm. The numbers of foci (clusters)
and total number of PNECs were normalized for the total
lung tissue area on the slide because many PNECs are
present in alveolar ducts. The total lung area was determined
on nonoverlapping photomicrographs of the whole section
at 2 magniﬁcation, which then underwent thresholding,
binary conversion, and area measurement.
SMA immunostaining (without any counterstain) was
quantiﬁed in photomicrographs within 1 mm of the pleural
surface (but excluding the pleura) by thresholding in the red
visibility range (224 to 255), followed by binary conversion
and measurement of area. These values were normalized for
the total area of the alveolar tissue in each photomicrograph
(excluding conducting airways and their associated blood
vessels). Quantiﬁcation of Trichrome staining was per-
formed using blue collagen staining without any hematox-
ylin counterstain by thresholding in the blue visibility range
(134 to 211), followed by binary conversion and area
measurement, again normalized for total tissue in each
photomicrograph.
Statistical Analysis
Groups were compared using the unpaired Student’s t-test,
with P < 0.05 deﬁned as the level of signiﬁcance.
Results
To assess possible roles for GRP in tissue injury responses
after radiation, mice were given 500 nmol/L ﬁnal concen-
tration of 77427, twice weekly, beginning 1 hour after
radiation. Lung tissues were harvested for inﬂation ﬁxation1250and staining at 2, 4, 6, 8, 10, and 20 weeks later. Bright ﬁeld
microscopy and ImageJ screening demonstrated altered
numbers of immunopositive cells as follows: macrophages
(CD68) only at 4 weeks, neuroendocrine (NE) cells (GRP,
PGP9.5) mainly at 6 weeks, activated TGF-b signaling
(pSmad2/3) only at 10 weeks, and myoﬁbroblasts (SMA) at
20 weeks (Figures 1, 2, 3 and 4). Trichrome staining was
performed only at the 20-week time point.
Increased numbers of alveolar macrophages have been
reported to occur in mouse lung between 1 and 4 monthsajp.amjpathol.org - The American Journal of Pathology
Figure 3 GRP blockade diminishes pSmad2/3þ cells in mouse lung at
10 weeks after radiation. A: Sham plus PBS group. B: Radiation plus PBS
group. C: Radiation plus 77427 group. D: Image analysis. AeC: Nuclear
pSmad2/3 immunostaining (black arrows) was signiﬁcantly elevated at 10
weeks after radiation (compared with negative nuclei counterstained with
methyl green, white arrows). Sham controls had relatively few pSmad2/3þ
cells; then the relative numbers of these cells increased more than fourfold
after radiation. *P < 0.001 for radiation plus PBS versus sham plus PBS
(fourfold increase) or radiation plus 77427; yP < 0.01 for radiation plus
77427 was only 30% elevated over sham plus 77427; zP < 0.001 for sham
controls given only 77427 had a doubling of pSmad2/3þ cells versus the
sham plus PBS group. Scale bars: 25 mm (AeC). V, blood vessel.
Figure 4 Increased SMA-immunostaining and collagen deposition 20
weeks after radiation is abrogated by GRP blockade. A: Normal SMA im-
munostaining (red) in sham plus PBS lung occurs in airway and vascular
smooth muscle. In subpleural lung (photomicrographs for ImageJ), a few
small blood vessels are present. B: Mice exposed to radiation plus PBS have
widespread, patchy SMAþ cells throughout the alveolar interstitium (white
arrows). C: In radiation plus 77427 mice, SMA immunostaining is mostly
restricted to normal small blood vessels. D: Normal trichrome staining (blue
to purplish blue) in sham plus PBS lung occurs around airways and blood
vessels. In the subpleural region shown here and used for ImageJ analysis,
blue outlines of small blood vessels are visible (black arrows). E: Mice
exposed to radiation plus PBS have collagen deposition in the alveolar
interstitium (some blue to purplish blue interstitium, white arrows), as
well as blue outlines of small blood vessels (black arrows). F: In radiation
plus 77427 mice, collagen is mostly restricted to small blood vessels (black
arrows). G: Quantitative image analysis was performed as detailed in
Materials and Methods. For both SMA and trichrome, *P < 0.0001 for
radiation plus PBS versus sham plus PBS; yP < 0.001 for radiation plus PBS
versus radiation plus 77427. Asterisks in A and C indicate pleural surface.
Scale bars: 25 mm (AeF). V, blood vessel.
GRP and Radiation Fibrosisafter radiation as part of an inﬂammatory phase.29,30 In
sham controls, we demonstrated scattered CD68þ cells both
in alveolar spaces and in the distal lung interstitium
(Figure 1A). At 4 weeks after radiation, CD68þ cells were
increased, almost exclusively localized to the alveolar
interstitium (Figure 1B). GRP blockade by 77427 reduced
this macrophage accumulation in the pulmonary interstitium
(Figure 1C). By quantitative image analysis using ImageJ,
the CD68þ cells in radiation plus PBS mice were nearly
threefold increased compared with sham plus PBS mice
(Figure 1D). We did not observe any signiﬁcant differences
in numbers of macrophages at the other time points.
Rare GRPþ and/or PGP9.5þ cells were detected in sham
controls (Figure 2, A and D), typically in bronchiolar
epithelium near branch points, which is a niche for epithelial
progenitor or stem cells in lung.31 At 4 weeks after radia-
tion, three of the eight mice had increased numbers of GRPþ
and PGP9.5þ PNECs (data not shown). By 6 weeks after
radiation, all animals had elevated numbers of GRPþ
(Figure 2B) and PGP9.5þ (Figure 2E) cells, increased up to
20-fold per square centimeter of lung (Figure 2G). This
PNEC hyperplasia was linear, manifested primarily as 10-
fold increase of small GRPþ foci with a mean of two cells
per focus. There were signiﬁcantly fewer PNECs when mice
were treated with 77427 (Figure 2, C, F, and G). Both the
GRPþ and PGP9.5þ cells were localized almost entirely to
small bronchioles (Figure 2, B and E) and yielded similar
results of quantitative image analysis (Figure 2G). There
was no difference in PCNA labeling of these cells. Inter-
estingly, many GRPþ cells also co-stained for CC10,
a Clara cellespeciﬁc marker (not shown), indicating thatThe American Journal of Pathology - ajp.amjpathol.orgthese may fall into the category of regenerative multipotent
cells after injury.31 There was no apparent difference in total
numbers of CC10þ cells at any time point (data not shown).
Phospho-Smad2/3 (pSmad2/3) is a recognized marker of
active TGF-b signaling, as occurs in bleomycin-induced
pulmonary ﬁbrosis,32 carbon tetrachlorideeinduced hepatic
ﬁbrosis, and glomerular ﬁbrosis.33,34 Ten weeks after mice
received 15Gy of thoracic radiation, comparedwith sham plus
PBS controls (Figure 3A), lungs had approximately fourfold
increased numbers of pSmad2/3þ cells, including ﬁbroblasts,
macrophages, endothelium, and epithelial cells, all of which
had nuclear immunostaining (Figure 3, BeD). GRP blockade
of radiation-exposed mice with 77427 reduced pSmad2/3-
immunopositive cells signiﬁcantly compared with radiation
plusPBSetreatedmice, representingonly a residual of 1.3-fold
increased cells compared with the corresponding sham
controls. It is unknownwhymice given 77427 alone had higher1251
Zhou et alpSmad2/3 immunostaining, but this was not associated with
evidence of increased ﬁbrosis (Figure 4).
Figure 4 presents results of two additional widely used
markers of ﬁbrosis: SMA (Figure 4, AeC and G), and
Masson’s Trichrome (Figure 4, DeG). SMA is expressed by
myoﬁbroblasts35 during pulmonary ﬁbrosis of diverse etiol-
ogies.36,37 In adult lung at baseline, SMA is normally present
in smooth muscle cells surrounding pulmonary vasculature
and airways (note “v” indicating small to medium blood
vessels in Figure 4, AeC). At 20 weeks after radiation (but
not before), mice demonstrated approximately three fold
increased SMA, determined as volume percentage of immu-
nostaining of the distal lung parenchyma (Figure 4, B and D).
Treatment with 77427 abrogated this increased SMA immu-
nostaining (Figure 4, C and D).
We also performed IHC staining for mature collagens
using Masson’s trichrome method with blue stain for
collagens (Figure 4, DeG). To permit ImageJ analysis by
selecting blue wavelengths, we omitted the hematoxylin
counterstain. Normal trichrome staining (blue to purplish
blue) was seen in sham plus PBS lung, which was around
airways and blood vessels. In the subpleural region, faint
blue outlines of small blood vessels could be seen. Notably,
mice exposed to radiation plus PBS had collagen deposition
in the alveolar interstitium, as well as blue outlines of small
blood vessels. Radiation plus 77427 mice had collagen
staining mostly restricted to small blood vessels (Figure 4F).Figure 5 GRP blockade diminishes or abrogates many cellular mecha-
nisms after radiation. At 4 weeks after radiation, the data indicate that GRP
increases CD68þ macrophages because GRP blockade with 77427 abrogates
the increase and macrophages are GRPRþ. At 6 weeks after radiation, GRP
promotes increased numbers of GRPþ/PGP9.5þ pulmonary neuroendocrine
cells (PNECs) consistentwithmultipotent (plastic) epithelial cells [airway (AR)
epithelium is GRPRþ]. At 10 weeks after radiation, there is increased
expression of pSmad2/3, indicating activation of TGF-b signaling. At 20weeks
after radiation, early interstitialﬁbrosis is evident as SMAþmyoﬁbroblasts and
collagen deposition in alveolar septa (pulmonary ﬁbroblasts are GRPRþ). All
these functional and/or phenotypic changes are reversed by GRP blockade.Discussion
The present study demonstrates that GRP blockade signiﬁ-
cantly mitigates parameters of radiation-induced pulmonary
ﬁbrosis in an established mouse model.24 It has already been
reported that PNEC triggered by reactive oxygen species
secrete GRP in response to lung injury.38 Either of two GRP-
blocking agents,39 smallmolecule 77427 or blocking antibody
2A11, can abrogate multiple parameters of oxidant-triggered
lung injury in animal models of reactive airways disease or
bronchopulmonary dysplasia.10,16 There is a logical precedent
for determining whether GRP promotes radiation ﬁbrosis. In
the hyperoxic preterm baboon model of bronchopulmonary
dysplasia, GRP blockade by 2A11 resulted in marked reduc-
tion in mesenchymal cell proliferation in the alveolar inter-
stitium.16 GRP also induces ﬁbroblast proliferation.40,41 This
observation led to the hypothesis that GRPmight contribute to
interstitial ﬁbrosis after thoracic radiation.
Radiation-induced ﬁbrosis mediated by GRP represents
the chronic phase of lung injury linked to a novel master
inﬂammatory circuit that regulates responses of diverse
inﬂammatory cell types.10 It has been known for decades that
PNEC hyperplasia can develop with exposure to oxidants41
or chronic inﬂammation.42 In the setting of chronic inﬂam-
mation, PNEC hyperplasia appears to be mainly a cell
differentiation response, with minimal proliferation of
PNECs.43 Furthermore, tumor necrosis factor (TNF)-1252a treatment of undifferentiated small cell lung carcinoma
cells in vitro can induce rapid NE differentiation.44
Despite the large body of evidence for oxidant-induced
PNEC hyperplasia and abrogation of PNEC hyperplasia by
antioxidant therapy in animal models38 and the induction of
NE cell differentiation by TNF-a,44 there has been no prior
report of increased numbers of PNECs after radiation expo-
sure. In the current study, PNEC hyperplasia occurred in
a predominantly linear pattern 4 to 6 weeks after a single
exposure to high-dose RT, peaking at 6 weeks. In hamsters
exposed to continuous 65% hyperoxia plus diethylnitros-
amine, induction of profound PNEC hyperplasia occurred
after 8 to 12 weeks.19 It remains unclear exactly why it takes
weeks for the PNEC hyperplasia to develop after radiation
exposure and in turn why so many months lapse before
radiation ﬁbrosis develops. As with other types of pulmonary
ﬁbrosis, we speculate that this delay may be related to the
timing of inﬂammatory cell accumulation and speciﬁc cyto-
kine production in the lung.45e47 It is recognized that radia-
tion ﬁbrosis may not be clinically evident for 5 months to
even a year after radiation exposure.48e50
In Figure 5, we present our modiﬁed working hypothesis
about how GRP might mediate lung injury after radiation.
Multiple chronic effects of radiation on lung are abrogated by
GRPblockade.At 4weeks after radiation, treatmentwith 77427
abrogates accumulation of CD68þmacrophages in the alveolar
interstitium. Activatedmacrophages have a high level ofGRPR
gene expression.10 Functionally, both GRP and bombesin have
been shown to promote macrophage activation, chemotaxis,
phagocytosis, and oxidative burst.9,51,52 Macrophage-derivedajp.amjpathol.org - The American Journal of Pathology
GRP and Radiation Fibrosiscytokines, such as TNF-a, IL-1, and IL-6, are recognized as
playing roles in the pathogenesis of radiation ﬁbrosis.30,46,53
The detection of increased numbers of GRPþ/PGP9.5þ
PNECs at 6 weeks after radiation suggests that macrophage-
derived cytokines could contribute in part to the observed
PNEC hyperplasia.
In the present study, many of the interstitial macrophages
are positive for pSmad2/3, indicating activation of TGF-b
signaling. TGF-b has been widely implicated in the etiology
of radiation ﬁbrosis.54 At 20 weeks after radiation, we
demonstrate early interstitial ﬁbrosis as SMAþ myoﬁbro-
blasts and collagen deposition in the alveolar interstitium. All
of the functional and phenotypic changes observed in the
present study are diminished by GRP blockade. We previ-
ously reported that pulmonary ﬁbroblasts are GRPRþ7 and
ﬁbroblasts from multiple sources proliferate in response to
GRP or bombesin.40,41 Peak levels of radiation ﬁbrosis have
been documented to occur at 5 to 9months after radiation.46,55
In conclusion, we here demonstrate that radiation-induced
PNEChyperplasiaoccurs as a novel cellular responseduring the
acute lung injury phase of radiation ﬁbrosis. Chronologically,
this cellular alteration in airway epithelialNEcell differentiation
follows peak macrophage accumulation and leads to increased
TGF-b signaling and the onset of interstitial ﬁbrosis with
myoﬁbroblast inﬁltration and collagen deposition in the
alveolar interstitium. By using GRP blockade in a deﬁnitive
experiment, we have determined that GRP plays a signiﬁcant
role in vivo in diminishing or abrogating multiple signiﬁcant
parameters on the pathway to radiation ﬁbrosis. It is likely that
the ultimate outcome of pulmonary ﬁbrosis is inﬂuenced by
many other cellular alterations and innate immune responses,
including altered regulation of angiogenesis, apoptosis, and
antioxidant defenses after radiation exposure.45,48e50,56,57 The
identiﬁcation of PNECs and GRP as key players in radiation
ﬁbrosis should lead to new roadmaps for scientiﬁc exploration
in pursuit of mitigating or protective agents to protect patients
from therapeutic or unintentional radiation injury.
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